Cancer metastases are commonly found in the lymphatic system. Like tumor blood angiogenesis, stimulation of tumor lymphangiogenesis may require the interplay of several tumor-derived growth factors. Here we report that members of the PDGF family act as lymphangiogenic factors. In vitro, PDGF-BB stimulated MAP kinase activity and cell motility of isolated lymphatic endothelial cells. In vivo, PDGF-BB potently induced growth of lymphatic vessels. Expression of PDGF-BB in murine fibrosarcoma cells induced tumor lymphangiogenesis, leading to enhanced metastasis in lymph nodes. These data demonstrate that PDGF-BB is an important growth factor contributing to lymphatic metastasis. Thus, blockage of PDGF-induced lymphangiogenesis may provide a novel approach for prevention and treatment of lymphatic metastasis.
Introduction
Tumors stimulate blood and lymphatic vessel growth by producing angiogenic factors. Although it is known that induc-The major cause of cancer mortality is metastasis, which relies tion of tumor angiogenesis is a complex process that involves on de novo formation of blood and lymphatic vessels (Fidler, the interplay of a dozen or more tumor-derived growth factors 2003). While blood vessels support tumor growth by providing (Carmeliet and Jain, 2000; Folkman, 1995;  Hanahan and Folknutrients and oxygen, and by removing waste products, the man, 1996), it is poorly understood how tumors induce lymphanfunction of tumor lymphatic vessels remains poorly understood giogenesis, and what its role is in tumor spread (Beasley et al., (Dyer et al., 2003) . One might expect that sprouting of lymphatic Williams et al., 2003) . Many of the recent research efforts vessels in the tumor would facilitate tumor immunity by providin studying lymphangiogenesis are focused on two members ing lymph node conduits for antigen-presenting cells. In reality, of the VEGF family, VEGF-C and VEGF-D, which interact with however, these conduits facilitate the spread of tumor cells to VEGFR-3, a lymphatic endothelial receptor (Alitalo and Carmelregional lymph nodes. Indeed, the lymphatics are the dominant iet, 2002) . Indeed, both VEGF-C and VEGF-D have been shown route for tumor cell spread in some of the most common cancer to enhance lymphatic metastasis when expressed at high levels types, such as breast and colon/rectal cancers .
in tumors (Makinen et al., 2001; Skobe et al., 2001; Stacker et Thus, understanding the molecular mechanisms that control al., 2001) . lymphangiogenesis and its functions will be an important step
In addition to members of the VEGF family, tumors with high in the development of therapeutic agents for prevention and lymphatic metastatic ability also express other growth factors at high levels (Relf et al., 1997) . For example, high levels of treatment of cancer metastasis.
PDGF-BB expression have been found in breast cancer tissues (Coltrera et al., 1995) . These distribution studies have raised the possibility that members of the PDGF family may contribute to tumor lymphangiogenesis and lymphatic metastasis. The PDGF family includes at least four structurally related members, PDGF-AA, -BB, -CC, and -DD (Kazlauskas, 2000) , that can form both homodimers and heterodimers (Heldin and Westermark, 1999) . Members of the PDGF family bind to tyrosine kinase receptors encoded by two genes, PDGFR-␣ and -␤. PDGF-BB is the only ligand that can activate both the PDGFR-␣ and -␤ (Hammacher et al., 1989) . Both genetic studies and our own recent work have demonstrated that members of the PDGF family are important angiogenic factors Lindahl et al., 1997) . Here we have established a murine lymphangiogenesis model to assess whether PDGF-BB plays a direct role in promoting lymphangiogenesis and metastasis. Our data demonstrate that PDGF-BB induces tumor lymphangiogenesis and metastatic spread to lymph nodes, and show that growth factors other than VEGFs can play key roles in these processes.
Results

PDGF-BB stimulates lymphatic vessel growth in vivo
To study the lymphangiogenic properties of PDGF-BB, we used a mouse corneal lymphangiogenesis model in combination with confocal microscopy to reveal specific markers that are exclusively expressed on lymphatic endothelial cells. Similar to FGF-2, PDGF-BB induced a robust angiogenic response in the mouse cornea (Supplemental Figures S1C-S1F and S1H-S1K). Within 2 weeks after growth factor implantation, PDGF-BBinduced corneal neovascularization was almost as potent as FGF-2-induced angiogenesis in this model (Supplemental Fig- ures S1B, S1D-S1G, and S1I-S1K). Thus, PDGF-BB is a potent angiogenic factor in vivo. Under physiological conditions, the corneal tissue lacks both blood vessels and lymphatic vessels (Cursiefen et al., 2002) . The only lymphatic vessels detected, using the lymphatic marker LYVE-1 (Banerji et al., 1999; , were the preexisting lymphatics in the limbus (Supplemental Figure S3A , LYVE-1). Implantation of the slow-release polymer without growth factors did not result in the growth of new lymphatic vessels (Supplemental Figure S3A , PBS). However, the inclusion of PDGF-BB potently stimulated growth of new lymphatic vessels sprouting from the existing limbal lymphatics ( Figures 1C, 1E , and 1G). These newly formed LYVE-1 almost equally potent in inducing blood and lymphatic angiogenesis ( Figures 1I and 1J ). These data demonstrate that PDGF-BB is a potent lymphangiogenic factor in vivo.
To further confirm their identity as lymphatic vessels, LYVEcompletely overlapping immunostaining patterns were detected 1-positive structures were costained with antibodies against between LYVE-1 and podoplanin (Supplemental Figures S2Apodoplanin and VEGFR-3, two other specific markers expressed S2C) or VEGFR-3 (Supplemental Figures S2D-S2F ). To demonon lymphatic vessels (Breiteneder-Geleff et al., 1999;  Kaipainen strate that LYVE-1 did not stain blood vessels, corneal sections et al., 1995) . Consistent with previous findings, both were double-stained with antibodies against LYVE-1 and CD34 and podoplanin are codistributed on the newly formed lymphatic (a specific marker expressed on blood vessels). Similar to CD31/ LYVE-1 double staining, LYVE-1 positive vessels lacked CD34 vessels (Kubo et al., 2002; . As expected, signals . These data confirm blocked by the anti-VEGFR-3 antibody and the sVEGFR-3-Fc ( Figures 3C-3E ). To further assess the blocking activity of these the LYVE-1 positive structures in neovascularized cornea as lymphatics and further validate the specificity of LYVE-1 anti-antagonists, we performed a modified Boyden chamber assay. Both antagonists effectively blocked the migration of VEGFR3/ bodies for lymphatic rather than blood vessel endothelium. Based on these findings, we chose LYVE-1 as a lymphatic PAE cells, the sVEGFR-3-Fc being more potent than the anti-VEGFR-3 antibody ( Figure 3F ). specific marker for the rest of our studies.
Having shown that these antagonists efficiently inhibited the VEGF-C/-D/VEGFR-3 system in vitro, we further investigated Stimulation of lymphangiogenesis by PDGF-AA and PDGF-AB their antagonistic effect in vivo. As expected, in the mouse corneal assay, the anti-VEGFR-3 antibody selectively blocked To determine whether other members of the PDGF family could also induce lymphangiogenesis and to compare their lymphan-VEGF-C-induced lymphangiogenesis but had no significant effects on blood angiogenesis ( Figures 3I, 3N , and 3O). The giogenic activity, the same amounts of PDGF-AA, -AB, and -BB were implanted in mouse corneas. Similar to PDGF-BB, PDGF-sVEGFR-3-Fc blocked both VEGF-C-induced blood and lymphatic angiogenesis ( Figures 3J, 3N , and 3O). By contrast, how-AA and -AB were also able to induce corneal lymphangiogenesis. However, the number of lymphatic vessels induced by ever, neither the anti-VEGFR-3 antibody nor the sVEGFR-3-Fc had any effect on PDGF-BB-induced blood or lymphatic PDGF-AA was significantly less than that induced by PDGF-AB and -BB ( Figures 2D-2I and 2K). PDGF-AB and -BB induced angiogenesis ( Figures 3K-3O ). Hence these results demonstrate that PDGF-BB-induced lymphangiogenesis is not mediated via similar numbers of lymphatic vessels in this system ( Figure 2K ). Since PDGF-AB and -BB, but not PDGF-AA, bind to PDGFR-the VEGF-C/-D/VEGFR-3 pathway. ␤ (Heldin and Westermark, 1990), these findings suggest that the PDGFR-␤ plays a critical role in mediating PDGF-induced PDGF-BB is a chemoattractant for primary lymphatic endothelial cells lymphangiogenesis. Similar to lymphangiogenesis, all three factors were also able to induce hemangiogenesis ( Figures 2A-2C The fact that the VEGF-C/-D/VEGFR-3 neutralizing agents had no inhibitory effect on PDGF-BB-induced lymphangiogenesis and 2G-2I). However, unlike lymphangiogenesis, the levels of hemangiogenesis were approximately equal in each case (Fig- suggests that PDGF-BB acts directly on lymphatic endothelial cells (LECs). To investigate this possibility, human, mouse, and ure 2J). Due to its potent lymphangiogenic activity, the remainder of our study was focused on PDGF-BB.
rat primary LECs were isolated. These LECs expressed lymphatic markers such as podoplanin and LYVE-1 ( Figures 4A-4C ). PDGF-BB and -AA stimulated migration of mouse and Remodeling of nascent lymphatic vessels Like blood angiogenesis, the formation of lymphatic vessels human LECs in a concentration-dependent manner (Figures 4D and 4E) . Similarly, VEGF-C, a known chemoattractant for LECs, stimulated by PDGF-BB was readily detectable at day 5 after implantation, and a maximal response was detectable at day 14 also induced cell motility in a concentration-dependent fashion. As expected, STI571, a potent PDGFR inhibitor, attenuated both after implantation (Supplemental Figures S3B, S3C, and S3G) . During this period, the primitive newly formed lymphatic vessels PDGF-BB-and -AA-induced cell migration ( Figures 4D and 4E ). Interestingly, this PDGFR inhibitor also partially inhibited VEGF-underwent remodeling. By day 14, vascular tree-like structures were found in the PDGF-BB-induced lymphatic vessels, and C-induced cell migration, suggesting that its inhibitory effect was not only limited to the PDGFR-signaling pathway. Similar some lymphatic vessels penetrated into the implanted PDGF-BB pellets. In addition, PDGF-BB-induced corneal blood ves-to mouse and human LECs, PDGF-BB significantly stimulated the migration of rat LECs ( Figures 4F and 4G ), but in common sels were remodeled from the primitive vascular plexuses into well-organized vasculatures ( Supplemental Figures S3B and with PDGF-AA and VEGF-C, it did not regulate the expression levels of Prox-1 in mouse LECs ( Figure 4H ). The anti-VEGF-C/ S3C). Similar vascular remodeling was also found in FGF-2induced lymphatic and blood vessels (Supplemental Figures -D/VEGFR-3 antagonists could not block PDGF-BB-induced cell migration of human LECs, whereas both neutralizing agents S3D and S3E). Quantification analysis showed that PDGF-BB and FGF-2 induced approximately equal numbers of lymphatic blocked VEGF-C-induced migration significantly ( Figure 3G ). In light of reports that the Tie2 receptor ligand angiopoietin-2 vessels (Supplemental Figures S3G) .
(ang-2) can induce lymphangiogenesis (Veikkola and Alitalo, 2002), we considered the possibility that PDGF-BB-induced
Blockage of VEGF-C/-D/VEGFR-3 does not inhibit PDGF-BB-induced lymphangiogenesis
lymphangiogenesis might operate via upregulation of Ang-2. However, Ang-2 expression levels were not affected by PDGF-One possible explanation for PDGF-BB-stimulated lymphangiogenesis is that the growth factor induced secondary activation BB stimulation in cells that are known to express PDGF recepof the well-characterized VEGF-C/-D/VEGFR-3 system. To extors ( Figure 4I ) (Furuhashi et al., 2004) . These data further supclude this possibility, we investigated the effects of an antiport the notion that PDGF-BB has a direct effect on LECs. mouse VEGFR-3 antibody and a soluble VEGFR-3-Fc, both of which are antagonists of the VEGF-C/-D/VEGFR-3 system.
Activation of intracellular signaling pathways of isolated primary LECs Firstly, we validated the ability of both reagents to block VEGF-C-induced endothelial cell activity in vitro by using the VEGFR-Stimulation of LEC motility by PDGF-BB suggested that this factor could activate intracellular signaling components. Indeed, 3-overexpressing porcine aortic endothelial (VEGFR-3/PAE) cell line. In the presence of VEGF-C, these cells underwent dramatic increased levels of phosphorylated Src (P-Src), Erk 1/2 (MAP kinases, P-Erk1/2), and Akt (protein kinase B) were detected in morphological changes from regular cell shapes into elongated spindle-like structures (Figures 3A, 3B, and 3E) . This VEGF-rat LECs upon PDGF-BB stimulation. The activation of these intracellular signaling components was both concentration-and C-induced cell morphological change was almost completely 
time-dependent (Figures 5A and 5B). Similarly, PDGF-AA and
Detection of PDGFRs on newly formed lymphatic vessels VEGF-C also induced increased levels of P-Src and P-Erk as compared with those of controls ( Figures 5C and 5D ). As ex-PDGF-BB exerts its biological functions via activation of two tyrosine kinase receptors, PDGFR-␣ and -␤ (Heldin and Wes-pected, the protein kinase inhibitor STI571 inhibited the phosphorylation levels of these intracellular components, in response termark, 1999). To study the expression of these receptors on corneal lymphatics, we used a combination of in situ RNA hy-to PDGF-BB and -AA, in a concentration-dependent manner ( Figures 5E and 5F ). Interestingly, this PDGFR inhibitor also bridization and antibody staining to colocalize mRNAs coding for PDGFR-␣ and -␤ with LYVE-1-positive vessels. Lymphatic significantly suppressed VEGF-C-induced phosphorylation of Src and Erk1/2 ( Figure 5G ), suggesting that this compound has vessels were detected using an anti-LYVE-1-specific antibody ( Figures 6C and 6D , brown color), and PDGF receptor signals a broad inhibitory effect on several tyrosine kinases. However, it should be emphasized that STI571 had little effect on VEGF-were determined using probes specific for PDGFR-␣ and -␤ . Both PDGFR-␣ and -␤ positive signals were C-tumor growth in vivo. Although the underlying mechanism of the differential effects by which STI571 acts in vitro and in vivo detected on PDGF-BB-induced lymphatic vessels ( Figures 6C  and 6D , arrows) and on blood vessel endothelial cells (Cao et is not known, it is possible that VEGF-C could utilize other signaling pathways to promote blood and lymphatic angio-al., 2003) . PDGFR-␣ and -␤ were also detected at the protein level in preimplanted corneal lymphatics as assessed by double genesis.
staining for PDGFR␣/␤ and LYVE-1 ( Figures 6E-6J , white arrows point to double positive signals in I and J). Further, to determine whether LECs in tissues other than cornea also expressed PDGFRs, we carried out RT-PCR using cDNA prepared from primary mouse dermal LEC. Again, both PDGFR-␣ and -␤ were detected in these cells ( Figures 6K and 6L ). These findings were further supported by detection of expression of both types of PDGF receptors on the mouse LEC using Affymetrix gene array analysis (S.C. and D.G.J., unpublished data).
PDGF-BB promotes primary tumor growth
To determine the role of PDGF-BB in promoting tumor growth, we transfected a murine fibrosarcoma cell line (T241) with cDNA coding for human PDGF-BB. Approximately 100 ng/ml PDGF-BB was secreted into the conditioned medium as quantified by a sensitive immunodetection assay. Despite a high level of expression, PDGF-BB did not appear to affect the growth rate of tumor cells in vitro ( Figure 7A ), suggesting that these cells lacked expression of the PDGFRs. However, implantation of PDGF-BB-expressing tumor cells into C57Bl/6 syngeneic mice resulted in accelerated tumor growth as measured by both tumor volume and weight (Figures 7B and 7C) . Similarly, expression of VEGF-C, a known lymphangiogenic and blood angiogenic factor, significantly stimulated tumor growth in vivo without affecting the growth rate of tumor cells in vitro. The stimulatory effect of PDGF-BB on primary T241-tumor growth was statistically significant as compared with control tumors (p Ͻ 0.001) ( Figures 7B and 7C ). Confocal microscopy analysis using CD31 as a blood vessel marker revealed a significantly higher density of microvessels present in the PDGF-BB-expressing tumors as compared with controls ( Figures 7D, 7E , 7G, and 7H). These tumor vessels appeared as disorganized and tortuous vascular plexuses with dilated microvessels ( Figure  7G ). A high density of malformed tumor vessels was also found in the VEGF-C-expressing tumors ( Figure 7F, CD31) . In contrast, relatively well-organized tumor blood vessels were found in wt and vector-transfected tumor sections ( Figures 7D and 7E) .
Thus, it appears that both PDGF-BB and VEGF-C are able to stimulate blood vessel growth in primary tumors.
PDGF-BB induces tumor lymphangiogenesis
Like blood-borne metastasis, lymphatic metastasis may rely on the outgrowth of host lymphatic vessels into the tumor tissue. To numbers of lymphatic vessels induced by PDGF-BB-and VEGF-C-expressing tumors were significantly greater than those of controls ( Figure 7I) .
To further delineate the role of PDGF-BB in induction of tumor lymphangiogenesis, we established the mouse corneal tumor model. Because of the corneal avascularity and lack of positive signals (Supplemental Figures S4H-S4J) . Notably, lymphatic vessels outside the borders of tumors were relatively lymphatics, tumor growth in the cornea excludes a primary involvement of any preexisting blood and lymphatic vessels.
well-organized with branches (dashes in B-E and G-J). In contrast, tumor lymphatic vessels appeared as disorganized vascu-Implantation of tumor tissues into the corneal micropockets resulted in the growth of tumors expanding from the micropock-lar plexuses generally lacking defined lymphatic vessel structures (Supplemental Figure S4H ). Similar to tumor blood vessels, ets to the limbus (Supplemental Figures S4A and S4F ). Corneal tumor neovascularization became directly visible by gross ex-these premature tumor lymphatic vessels seemed to be leaky and resulted from fusion of lymphatic capillaries into large lu-amination 2 weeks after implantation. These newly formed tumor vessels, sprouting from the limbal vessels, infiltrated the entire mens. Triple staining of tumor cells (GFP-positive) and blood and lymphatic vessels revealed that these premature tumor area of the tumor tissue. PDGF-BB-expressing tumors were more potent stimulators of angiogenesis in the cornea than wt lymphatic vessels were distributed throughout the PDGF-BBexpressing tumors, with nonoverlapping patterns from blood tumors, and some of the PDGF-BB-induced vessels appeared as disorganized vascular plexuses (Supplemental Figure S4F) . vessels (Supplemental Figure S4J) . In contrast to PDGF-BBexpressing tumors, the distribution of wt lymphatic vessels was Indeed, immunohistochemical analysis revealed that PDGF-BBexpressing tumors contained a high vascular density with poten-only limited to the border of the implanted tumor, and no tumor lymphatics were detected (Supplemental Figures S4C and S4E) . tially tortuous and leaky features at the leading edges (Supplemental Figure S4G, arrows) . In contrast, wt tumors lacked such Most of these lymphatic vessels remained outside the tumor tissue and appeared as well-structured vessels. Quantification a disorganized vascularity (Supplemental Figure S4B) .
Like blood neovascularization, lymphatic vessels sprouting analysis showed that tumor-produced PDGF-BB significantly increased the number of blood and lymphatic vessels in this from the existing limbal lymphatics infiltrated the central region of PDGF-BB-expressing tumors as defined by LYVE-1 and GFP mouse tumor model (Supplemental Figure S4K and S4L) . These Rat LEC were starved in serum-free medium for 12 hr and incubated with various concentrations of PDGF-BB for 10 min (A), with 100 ng/ml of PDGF-BB at different time points (B), with 100 ng/ ml of PDGF-AA at different time points (C), or with 500 ng/ml VEGF-C at different time points (D) as indicated. Rat LECs were incubated for 10 min with 100 ng/ml of PDGF-BB-(E) and -AA (F), or 500 ng/ml of VEGF-C (G), in the absence and presence of various concentrations of STI571 as indicated. Equal amounts of cell lysates were analyzed by SDS-PAGE/Western blotting and probed with specific antibodies against active forms of Src, Erk1/2 or Akt. The intensity of each band was quantified.
data demonstrate that PDGF-BB induces tumor growth of lym- Figures 8A-8D ). H&E staining revealed the presence of invasive phatic vessels that consist of relatively malformed, premature, tumor cells in lymph nodes of PDGF-BB-and VEGF-C-tumor and probably leaky structures. Like blood vessels, such premabearing mice. These lymphatic tumor lesions were approxiture lymphatic vessels may contribute to lymphatic metastasis. mately 20-fold larger than the lymph nodes of healthy animals or animals with wt or vector-transfected tumors as measured by weight and volume ( Figures 8E and 8F) . Remarkably, it appeared PDGF-BB promotes lymphatic metastasis that PDGF-BB-induced lymphatic metastatic lesions were larger Stimulation of tumor lymphangiogenesis by PDGF-BB raised than VEGF-C-induced lymphatic metastases (p Ͻ 0.05, Figure the possibility that this factor might promote lymphatic metasta-8E). In contrast, neither wt nor vector-transfected tumors resis. We established a mouse lymphatic metastatic model in sulted in visible metastases in regional lymph nodes (Figures which subcutaneous T241 tumors were grown in the middle 8A and 8D-8F). Histological examination confirmed that GFPdorsum. After removal of primary tumors, autopsy analysis positive PDGF-BB or VEGF-C transfected tumor cells were showed that a majority of the PDGF-BB tumor-bearing animals developed metastatic lesions of axillary lymph nodes (n ϭ 8, present in axillary lymph nodes, whereas lymph nodes of control
Blockage of PDGF receptor activation inhibited PDGF-BB-induced lymphangiogenesis and tumor growth
To determine if inhibitors of the PDGF receptors could affect PDGF-BB-induced tumoral blood and lymphatic vessel growth, STI571 (50 mg/kg body weight/day) was used to treat tumorbearing mice. This dose was previously reported to sufficiently block PDGFR activation (Hwang et al., 2003; Uehara et al., 2003) . Administration of STI571 significantly reduced tumor burden as measured by weight and volume after treatment (Supplemental Figures S5A and S5B) . Interestingly, the number of tumor lymphatic vessels was lower in the STI571-treated tumors (Supplemental Figure S5C , S5D, and S5H) than in the PBS-treated tumors. Similarly, the number of blood vessels in the STI571treated tumors was also significantly reduced compared to controls (Supplemental Figure S5G) . In contrast, STI571 did not significantly block VEGF-C-induced tumor growth, blood angiogenesis, or lymphangiogenesis (Supplemental Figures S5A and  S5E-S5H) . These data suggest that activation of PDGF receptors is critical for PDGF-BB-induced lymphangiogenesis.
Discussion
Spontaneous lymphatic metastases are the consequence of a complex metastatic process that includes: (1) dissemination of malignant cells from a primary tumor to the lymphatics; (2) transport of tumor cells via the lymphatics to local lymph nodes;
(3) settlement of tumor cells in the lymph nodes; and (4) growth of metastatic tumors in the lymph nodes. Each of these steps is critical in facilitating clinical detection of lymphatic metastases in cancer patients. The question of whether tumor lymphatics are functional remains controversial (Padera et al., 2002; Skobe et al., 2001; Stacker et al., 2001) . To enter the lymphatic system, tumor cells must remain in physical contact with lymphatic vessels. Although the question of how tumor cells enter the lymphatic vessels remains to be solved, tumor cells may gain access into the lymphatic system by inducing intratumoral lymphangiogenesis or by co-opting preexisting lymphatics in the surrounding tissue (Beasley et al., 2002; Williams et al., 2003) . A great deal of the recent work in lymphangiogenesis research has been focused on two members of the VEGF family, VEGF-C and -D, which interact with VEGFR-3. Both VEGF-C and -D have been found to act on isolated lymphatic endothelial tins, FGFs, PDGF, etc. The instability of the tumor cell genome that may switch on many growth factors during malignant progression further suggests that multiple factors may be involved in controlling lymphangiogenesis in tumors (Folkman, 2002) . Among cancer-produced growth factors, expression of memmice lacked detectable GFP-positive tumor cells (Figures 8A- bers of the PDGF family has constantly been reported at high 8C). None of the PDGF-BB, VEGF-C, or control tumor-bearing levels, particularly in breast cancers (Ariad et al., 1991) . PDGFmice had visible or microscopic pulmonary metastases as de-AA and -BB do not require proteolytic processing for conversion tected by histological examination (data not shown). In suminto active forms (Heldin and Westermark, 1999) . Previous work mary, these results demonstrate that PDGF-BB is a potent on elucidating the role of PDGFs in tumor growth has mainly lymphangiogenic factor that promotes lymphatic metastasis in focused on their direct impact on tumor cells . Recent work performed in our lab, alongside other labs, mice.
Figure 7. Stimulation of tumor growth, angiogenesis, and lymphangiogenesis
A: Growth rates of vector-, PDGF-BB-, VEGF-Ctransduced or wt tumor cells in vitro. T241 tumor cells were seeded at a density of 1 ϫ 10 4 cells/ well in 24-well plates, and triplicates of each cell line were counted at indicated time points (Ϯ SEM). B: Tumor volumes were measured at indicated time points and the data are presented as mean determinants (Ϯ SEM). C: Tumors were weighed at day 13 after implantation and the data are presented as mean determinants (Ϯ SEM). ***p Ͻ 0.001. D-G: Tumor blood vessels and lymphatic vessels were double labeled for CD31 (red) and LYVE-1 (blue). Tumor cells in E-G are GFP-positive (green). Arrows in LYVE-1 panel point to newly formed lymphatic vessels. T ϭ tumor. Scale bar ϭ 100 m. Quantification of CD31 (H) and LYVE-1 (I) positive signals (n ϭ 7 different optical fields). **p Ͻ 0.01; ***p Ͻ 0.001.
has demonstrated that PDGF-BB and other members of this that PDGF-BB is as potent as VEGF-C in inducing tumor lymphangiogenesis and in promoting lymphatic metastasis. Thus, lymph-family are important angiogenic factors . In this paper we show that members of the PDGF family display angiogenesis and lymphatic metastasis are regulated by multiple factors. Further, our work suggests that PDGF-BB may be a direct potent lymphangiogenic activity. This is based on the following evidence: (1) both mRNA and proteins of the PDGF survival factor for newly formed lymphatics since PDGF-BB activates the Akt kinase, which promotes antiapoptotic sig-receptors are localized on newly formed lymphatic vessels; (2) both PDGFR-␣ and -␤ are detected in isolated primary lymphatic naling. Deletion of PDGF-B or PDGFR-␤ genes leads to homozy-endothelial cells; (3) PDGF-BB stimulates motility of primary LEC in vitro; (4) in isolated LEC, PDGF-BB activates intracellular gous lethality at birth. Among the cardiovascular abnormalities, microvascular hemorrhage and development of edema seem signaling pathways, such as the MAP kinases Erk1/2 and Akt, in a way similar to that observed for VEGF-activated signaling to be the major cause of lethality. Although lack of pericyes/ vascular smooth muscle cells (PC/VSMC) in the developing vas-in endothelial cells (Eriksson et al., 2003) ; and (5) VEGF-C/-D-VEGFR-3 neutralizing reagents do not block PDGF-BB-induced culatures is the most obvious reason for this hemorrhagic phenotype and blood vessel leakage (Leveen et al., 1994 ; Soriano, lymphangiogenesis in vitro and in vivo. We conclude that PDGF-BB is a direct lymphangiogenic factor. Our work demonstrates 1994), tissue edema could also be, in part, due to inappropriate development of the lymphatic system. In the present study, we gene in mice arrests lymphatic budding from veins, resulting in embryos lacking lymphatic vasculature (Wigle and Oliver, 1999) . have shown that PDGF-BB is a potent lymphangiogenic factor in the adult animals. Our studies should be validated in the Thus, it is important to study whether Prox-1 regulates expression levels of PDGF-BB. Two recent independent studies using future by the use of genetic models including PDGFs and their receptor knockin and knockout mice. It is possible that this Affymetrix gene array analysis show that overexpression of Prox-1 cDNA in blood vascular and lymphatic endothelial cells factor also plays a critical role in the establishment of the lymphatic vasculature during embryonic development. The tissue does not seem to induce PDGF-BB expression Petrova et al., 2002) . Prox-1 induces differentiation of edema observed in the PDGF-B/PDGFR-␤ knockout mice could also be due to a default drainage function of the lymphatic blood vascular endothelial cells toward the lymphatic lineage. The fact that PDGF-BB does not induce Prox-1 expression system. In physiological conditions, only initial lymphatics lack mural cells. It still remains unknown, however, if the lymphatic suggests that PDGF-BB-induced lymphatic endothelial cell differentiation and assembly of lymphatic vessels are mediated vessels in the PDGF-B/PDGFR-␤ knockout mice lack PC/ VSMC, which are required to maintain the physiological function via a pathway separated from that activated by Prox-1. These findings further suggest that although PDGF/PDGFR and VEGF-of the lymphatic system. These interesting issues remain to be further studied using genetic PDGF-B or PDGFR-␤ knockout C/VEGFR-3 have overlapping developmental functions on lymphatic system, the molecular mechanisms by which PDGF/ models.
The homeobox gene Prox-1 is an essential early transcrip-PDGFR-and VEGF-C/-D/VEGFR-3 induce lymphangiogenesis may be regulated by different sets of genes. It is possible that tion factor for lymphatic development. Deletion of the Prox-1
Mouse corneal neovascularization assay
there is a tissue-specific overlapping role between the VEGF-The mouse corneal angiogenesis assay was performed as previously de-C/VEGFR-3 and the PDGF/PDGFR signaling pathways in reguscribed and knockout mice. The differential roles of VEGF-C/VEGFR-3 Mouse corneal tumor model and PDGF/PDGFR signaling in the regulation of lymphangiogen-Implantation of tumor tissues in the mouse cornea was carried out according esis should also be further studied.
to previously described procedures (Muthukkaruppan and Auerbach, 1979) The Prox-1 gene is involved in regulating early events of (see Supplemental Experimental Procedures for a detailed description). lymphatic development Wigle and Oliver, 1999) . Perhaps a Prox-1 independent control gene exists that VEGFR3/PAE cell shape changes and motility assay regulates lymphatic vessel growth, which could be driven by Analysis of VEGFR-3/PAE cell shape changes and motility was carried out as previously published (Cao et al., 1998 ) (see Supplemental Experimental the PDGF system at later events. It is also possible that the Procedures for a detailed description). expression of Prox-1 in newly sprouting vessels is maintained after PDGF-BB treatment, even though the expression level Lymphatic endothelial cell motility assay is not increased. This basal expression level may already be Murine LECs were isolated from skin by immunobead selection using an sufficient for maintaining lymphatic differentiation. Further, proantibody targeting mouse LYVE-1. Human LECs were isolated as previously liferation of LEC may not necessarily lead to elevation of Prox-1 described (Nisato et al., 2004) . Expression of podoplanin and LYVE-1 signals was detected by staining nonpermeablized cells with a rabbit anti-human expression. These important issues need to be further explored podoplanin antibody or a rabbit anti-mouse LYVE-1 antibody. The motility using genetic models.
responses of human and murine LECs to PDGF-AA, -BB, or VEGF-C were
The mouse corneal tumor model is particularly useful to assayed using a modified Boyden chamber technique previously described distinguish newly formed lymphatic vessels induced by tumors (Cao et al., 1998) . The neutralizing effect of an anti-mouse VEGFR-3 antibody and the preexisting host vessels, as the cornea lacks both blood or an sVEGFR-3-Fc on PDGF-BB-induced cell migration of human LECs vessels and lymphatic vessels. Our data clearly demonstrate growth and metastasis through the following three mechanisms: 3Ј; and for PDGFR-␤: forward; 5Ј-GGACGCTGCGGGTGG-3Ј and reverse;
(1) direct stimulation of tumor cell growth, (2) stimulation of 5Ј-AACTCGCTGGTCTTGAACGTC-3Ј. The amplification program consisted angiogenesis, and (3) stimulation of lymphangiogenesis and meof 94ЊC for 1 min, 60ЊC for 1 min, and 72ЊC for 1 min for a total of 35 cycles. tastasis. Thus, development of antagonists for PDGF-BB and other members of the PDGF family may be an important ap-Western blot analysis proach for control of tumor growth and metastasis.
Western blot analyses of lysates from primary rat LECs were performed according to previously published methods (Eriksson et al., 2003 ) (see Sup-
Experimental procedures
plemental Experimental Procedures for a detailed description).
Animals
In situ hybridization Female and male 6-to 7-week-old C57Bl/6 mice were acclimated and caged Detection of PDGFR-␣ and -␤ in corneal tissues by in situ hybridization was in groups of six or less. Animals were anaesthetized by an injection of a performed according to recent published procedures using two independent mixture of dormicum and hypnorm (1:1) before all procedures and sacrificed oligoprobes complementary to PDGFR-␣ (nucleotides 423-470 and 3083by a lethal dose of CO 2 followed by cervical dislocation. All animal studies 3130) and PDGFR-␤ (946-996 and 2610-2657) . Briefly, were reviewed and approved by the animal care and use committee of the slides were exposed on phosphoimager screen overnight to confirm the in situ hybridization. For immunohistochemistry, the same sections were North Stockholm Animal Board. stained with a rabbit anti-mouse LYVE-1 antibody, and positive signals were research grants of Y.C.'s laboratory received from the Swedish Research Council, The Swedish Heart and Lung Foundation, the Swedish Cancer developed with a streptavidin peroxidase kit (Vectastain ABC kit, Vector laboratories, Burlingham, CA, USA) combined with a Sigma-Fast-DAB perox-Foundation, the Karolinska Institute Foundation, and the Å ke Wibergs Foundation. Y.C. is supported by the Swedish Research Council. D.G.J. gratefully idase substrate (Sigma Aldrich, Steinheim, Germany). To visualize the in situ hybridization signal, slides were dehydrated, dipped into photo emulsion, acknowledges the financial support of the Medical Research Council, the Association for International Cancer Research, and Cancer Research UK and exposed for 6 weeks in the dark. Finally, sections were developed, counterstained with cresyl violet, and analyzed under light and dark field of (C581/A3865). D.G. is supported, through L. Olson, by the Swedish Research Council and USPH grants. We thank Dr. Elisabeth Buchdunger at Novartis a Zeiss Axiophot microscope.
Pharma for kindly providing us STI71 for this study. Immunohistochemistry Frozen corneal sections of 6 m thickness were double-stained for LYVE-1 and each of the PDGFRs according to standard immunohistochemical procedures. A mixture of a rabbit anti-mouse LYVE-1 antibody (Banerji et al.,
